Collaborations between industry and the NHS are key for achieving optimal, patient-centric cancer care in England¹. In lung cancer, the journey starts with adequate screening without which patients may not receive early diagnosis and prompt access to the right treatment for them.

Through a moderated panel discussion, we will showcase how collaborations between the NHS and the pharmaceutical industry can help support access to early diagnosis, improve understanding of the symptoms of lung cancer, and ultimately shift the dial closer to realising the importance of early diagnosis and screening in cancer care.

Delegates will:

-        Hear some of the challenges in lung cancer screening

-        Learn about a best practice case study for a screening collaboration between AstraZeneca and the NHS in lung cancer

-        Hear a panel discussion about the applicability of these findings

-        Be able to ask the panel any questions relating to the topics discussed during the session

References:

1.      NHS England. Partnerships and relationships. Cited at www.england.nhs.uk/ourwork/part-rel (last accessed May 2022)

GB-36036 May 2022